Biktarvy (Bictegravir/Emtricitabine/Tenofovir alafenamide) for HIV

Overview Biktarvy is a prescription drug approved by the Food and Drug Administration (FDA) as a complete regimen to treat HIV-1 infection in adults. Biktarvy is a combination drug composed of Bictegravir, Emtricitabine, and Tenofovir alafenamide, which are also known respectively by the abbreviations BIC, FTC, and TAF. Bictegravir is an integrase strand transfer inhibitor (INSTI). Emtricitabine and Tenofovir alafenamide are both medications of the nucleoside reverse transcriptase inhibitor (NRTI) class. All three drugs are believed to work by preventing HIV from replicating in cells. How do I take it? Prescribing information states that Biktarvy is taken once daily. Biktarvy comes in tablet form. Side effects The FDA-approved label for Biktarvy lists common side effects including headache, diarrhea, and nausea. Rare but serious side effects listed for Biktarvy include kidney and liver problems, worsening condition in cases of hepatitis B, and immune reconstitution syndrome (an inflammatory disorder). For more details about this treatment, visit: Biktarvy – Gilead https://www.biktarvy.com/